| Metric | Value | Detail |
|---|---|---|
| Revenue | $12.0B | +8.9% YoY |
| Net income | $4.0B | 32.9% margin |
| Gross margin | n/a | No gross profit line in the SEC data |
| Operating margin | 34.8% | Operating income / revenue |
| Return on equity | 21% | Net income / equity |
| Return on assets | 15% | Net income / assets |
| Revenue growth (YoY) | +8.9% | FY2024 to FY2025 |
| Revenue 3-yr CAGR | +10.4% | Compound annual |
| Diluted EPS | $15.32 | FY2025 |
| Debt-to-equity | n/a | No long-term debt figure in the SEC data |
| Current ratio | 2.90 | Current assets / liabilities |
| Cash & equivalents | $5.1B | Balance sheet |
| Total assets | $25.6B | FY2025 year-end |
| Shareholders’ equity | $18.7B | FY2025 year-end |
| Share price | $504.26 | Delayed · 2026-10-02 |
| Market cap | $127.8B | Price × shares outstanding |
| P/E ratio | 32.3 | Market cap / net income |
| P/S ratio | 10.6 | Market cap / revenue |
| Dividend yield | n/a | No dividend in the SEC data |
Stock fundamentals · FY2025 · SEC 10-K data
VERTEX PHARMACEUTICALS INC (VRTX) stock fundamentals
VERTEX PHARMACEUTICALS INC (VRTX) reported $12.0B in revenue and $4.0B in net income in fiscal 2025, a 32.9% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $127.8B at a delayed share price. It scores 65/100 on WealthyBud's Investor Score, ranking #19 of 103 covered companies. Score is research, not investment advice.
Revenue (FY2025)
$12.0B
▲ +8.9% YoY
Net income
$4.0B
32.9% net margin
Market cap
$127.8B
Price $504.26 · delayed
P/E ratio
32.3
Price / earnings
Return on equity
21%
Net income / equity
Investor Score
65/100
#19 of 103 covered
VERTEX PHARMACEUTICALS INC fundamentals at a glance
The table summarizes VERTEX PHARMACEUTICALS INC's key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is VERTEX PHARMACEUTICALS INC?
VERTEX PHARMACEUTICALS INC posted a 32.9% net margin in fiscal 2025, turning $12.0B of revenue into $4.0B of net income. Its return on equity was 21% and its return on assets 15%.
Is VERTEX PHARMACEUTICALS INC growing?
VERTEX PHARMACEUTICALS INC's revenue changed +8.9% in fiscal 2025 and compounded at +10.4% a year over three years, reaching $12.0B. Diluted earnings per share were $15.32 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2021 | $7.6B | First year shown |
| 2022 | $8.9B | +17.9% |
| 2023 | $9.9B | +10.5% |
| 2024 | $11.0B | +11.7% |
| 2025 | $12.0B | +8.9% |
How is VERTEX PHARMACEUTICALS INC valued?
VERTEX PHARMACEUTICALS INC carries a market capitalization of $127.8B at a delayed share price of $504.26. It trades at 32.3 times earnings and 10.6 times sales. Its dividend yield is not shown because its SEC data shows no dividend for the year. Its Value subscore is 30/100 across the covered universe.
How financially healthy is VERTEX PHARMACEUTICALS INC?
VERTEX PHARMACEUTICALS INC ended fiscal 2025 with $5.1B in cash, a debt-to-equity ratio that is not available because the SEC data has no long-term debt figure and a current ratio of 2.90. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is VERTEX PHARMACEUTICALS INC's Investor Score?
VERTEX PHARMACEUTICALS INC scores 65/100 on WealthyBud's Investor Score, #19 of 103 covered companies as of 2026-10-02. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
65/100
#19 of 103 covered companies
Subscores are percentile ranks (0–100) across the 103 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
VERTEX PHARMACEUTICALS INC (VRTX) stock FAQ
How much revenue does VERTEX PHARMACEUTICALS INC make?
VERTEX PHARMACEUTICALS INC (VRTX) reported $12.0B in revenue in fiscal 2025, +8.9% versus the prior year, according to its SEC 10-K filing. Its revenue compounded at +10.4% a year over three years.
Is VERTEX PHARMACEUTICALS INC profitable?
Yes. VERTEX PHARMACEUTICALS INC earned $4.0B in net income in fiscal 2025, a 32.9% net margin. Its return on equity was 21% and its return on assets 15%. These figures come from its latest 10-K.
How fast is VERTEX PHARMACEUTICALS INC growing?
VERTEX PHARMACEUTICALS INC's revenue changed +8.9% year over year in fiscal 2025 and compounded at +10.4% a year over three years. Growth is one of five inputs to its WealthyBud Investor Score, scored 43/100 versus the covered universe.
What is VERTEX PHARMACEUTICALS INC's market cap and P/E ratio?
VERTEX PHARMACEUTICALS INC has a market capitalization of $127.8B at a delayed share price of $504.26. It trades at 32.3 times earnings and 10.6 times sales. Its dividend yield is not shown because its SEC data shows no dividend for the year. Prices are delayed and illustrative.
What is VERTEX PHARMACEUTICALS INC's WealthyBud Investor Score?
VERTEX PHARMACEUTICALS INC scores 65/100, ranking #19 of 103 covered companies as of 2026-10-02. The score is a percentile blend of growth (43), profitability (88), returns on capital (68), balance-sheet strength (94) and value (30). It is a research opinion, not investment advice.
Where does this VERTEX PHARMACEUTICALS INC financial data come from?
Fundamentals come from VERTEX PHARMACEUTICALS INC's annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from VERTEX PHARMACEUTICALS INC’s FY2025 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-10-02. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.
Related
More large-cap stocks
Stocks
BRISTOL-MYERS SQUIBB COMPANY (BMY)
$123.9B market cap · Investor Score 43/100
View StocksPROGRESSIVE CORP (PGR)
$121.6B market cap · Investor Score 67/100
View StocksBooking Holdings Inc. (BKNG)
$119.3B market cap · Investor Score 67/100
View ResearchU.S. Stock Market Statistics (2026)
Market cap, valuation and concentration data across the U.S. stock market.
View